Literature DB >> 13052697

Identification of a thromboplastin inhibitor in serum and in plasma.

G F LANCHANTIN, A G WARE.   

Abstract

Keywords:  BLOOD; THROMBOPLASTIC SUBSTANCES

Mesh：

Substances：

Year:  1953        PMID： 13052697      PMCID： PMC438352          DOI： 10.1172/JCI102749

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  8 in total

1.  [Hemophilia and hemophilic syndrome; pathogenesis and treatment].

Authors:  R HONORATO
Journal:  Rev Med Chil       Date:  1952-01       Impact factor: 0.553

2.  Co-thromboplastin, a probable factor in coagulation of blood.

Authors:  F D Mann; M Hurn
Journal:  Am J Physiol       Date:  1951-01

3.  On the role of a protein inhibitor in the first stage of blood coagulation.

Authors:  S FIALA
Journal:  Arch Int Physiol       Date:  1951-02

4.  The clot accelerating effect of dilution on blood and plasma. Relation to the mechanism of coagulation of normal and hemophilic blood.

Authors:  L M TOCANTINS; R T CARROLL; R H HOLBURN
Journal:  Blood       Date:  1951-08       Impact factor: 22.113

5.  A thermolabile inhibitor of plasma coagulation.

Authors:  S FIALA
Journal:  Nature       Date:  1951-02-17       Impact factor: 49.962

6.  An improved one-stage prothrombin method.

Authors:  A G WARE; R STRAGNELL
Journal:  Am J Clin Pathol       Date:  1952-08       Impact factor: 2.493

7.  The relationship of plasma prothrombin concentration and the degradation rate of serum "prothrombin-converting factor" during dicumarol therapy.

Authors:  R F JACOX; R F BAYS
Journal:  Blood       Date:  1950-04       Impact factor: 22.113

8.  The prothrombin conversion accelerator of serum (SPCA): its partial purification and its properties compared with serum AC-globulin.

Authors:  B ALEXANDER; R GOLDSTEIN; G LANDWEHR
Journal:  J Clin Invest       Date:  1950-07       Impact factor: 14.808
  8 in total
  10 in total

1.  Studies on the differences in activity of lung and brain thromboplastin.

Authors:  H J WEISS; J W EICHELBERGER; W H CROSBY
Journal:  J Clin Invest       Date:  1961-02       Impact factor: 14.808

2.  [On the coagulation activity of human milk].

Authors:  M W HESS
Journal:  Blut       Date:  1961-08

3.  The role of proconvertin and Stuart factor in the inactivation of tissue thromboplastin by serum.

Authors:  F HERMANSKY; J VITEK
Journal:  Experientia       Date:  1960-10-15

4.  Inactivation of thromboplastin in human blood.

Authors:  T H SPAET; E S GARNER
Journal:  J Clin Invest       Date:  1955-12       Impact factor: 14.808

5.  Studies on the clot-promoting activity of glass.

Authors:  A DE VRIES; E SHAFRIR
Journal:  J Clin Invest       Date:  1956-11       Impact factor: 14.808

6.  [New concepts on the mechanism of blood coagulation].

Authors:  R MARBET; A WINTERSTEIN
Journal:  Experientia       Date:  1954-07-15

7.  Isolation of the tissue factor inhibitor produced by HepG2 hepatoma cells.

Authors:  G J Broze; J P Miletich
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

8.  Inhibitor of the factor VIIa-tissue factor complex is reduced in patients with disseminated intravascular coagulation but not in patients with severe hepatocellular disease.

Authors:  M S Bajaj; S V Rana; R B Wysolmerski; S P Bajaj
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

9.  [Hemophilia, deficiency condition or excess of antibodies?].

Authors:  E Hecht
Journal:  Klin Wochenschr       Date:  1966-07-15

Review 10.  Tissue factor pathway inhibitor: structure-function.

Authors:  George J Broze; Thomas J Girard
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.